The US Commerce Department has said certain specialty drugs and their ingredients from India and 19 other economies, including the EU, Japan, Britain and South Korea, will face no tariff under a 100% levy on patented pharmaceuticals that reaches all covered companies from September 29. The zero rate covers rare-disease treatments, fertility drugs, cell and gene therapies, antibody-drug conjugates and animal medicines, and applies because these jurisdictions have or are finalising trade and security agreements with Washington. Generic drugs are outside the Section 232 (a US law allowing tariffs on national-security grounds) measures, a point that matters for major generic exporters such as India.